{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:36:14Z","timestamp":1769607374480,"version":"3.49.0"},"reference-count":46,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,5,31]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite vitamin K antagonists (VKA) being the gold standard in the prevention of thromboembolic events in antiphospholipid syndrome (APS), non-vitamin K antagonists oral anticoagulants\/direct oral anticoagulants (DOACs) have been used off-label.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to perform a systematic review comparing DOACs to VKA regarding prevention of thromboembolic events, occurrence of bleeding events and mortality in patients with APS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An electronic database search was performed through MEDLINE, CENTRAL and Web of Science. After data extraction, we pooled the results using risk ratio (RR) and 95% CI. Heterogeneity was assessed using the I\u00b2. The outcomes considered were all thromboembolic events as primary, and major bleeding, all bleeding events and mortality as secondary. Evidence confidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation methodology.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 7 studies and a total of 835 patients for analyses. Thromboembolic events were significantly increased in DOACs arm, compared with VKA\u2014RR 1.69, 95%\u2009CI 1.09 to 2.62, I\u00b2\u201424%, n=719, 6 studies. In studies using exclusively rivaroxaban, which was the most representative drug in all included studies, the thromboembolic risk was increased threefold (RR 3.36, 95%\u2009CI 1.53 to 7.37). The risks of major bleeding, all bleeding events and mortality were not significantly different from control arm. The grade of certainty of our results is very low.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Current evidence suggests DOACs use, particularly rivaroxaban, among patients with APS, is less effective than VKA since it is associated with 69% increased risk of thromboembolic events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>CRD42020216178.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001678","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T12:36:13Z","timestamp":1626093373000},"page":"e001678","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3351-1387","authenticated-orcid":false,"given":"Nazariy","family":"Koval","sequence":"first","affiliation":[{"name":"Universidade de Lisboa Faculdade de Medicina, Lisbon, Portugal"}]},{"given":"Mariana","family":"Alves","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Farmacologia Clinica e Terap\u00eautica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Medicina III, Hospital Pulido Valente (CHULN), Lisboa, Portugal"},{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"Rui","family":"Pl\u00e1cido","sequence":"additional","affiliation":[{"name":"Centro Cardiovascular da Universidade de Lisboa (CCUL), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Cardiology Department, Hospital Universit\u00e1rio de Santa Maria (CHULN), Lisboa, Portugal"}]},{"given":"Ana G","family":"Almeida","sequence":"additional","affiliation":[{"name":"Centro Cardiovascular da Universidade de Lisboa (CCUL), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Cardiology Department, Hospital Universit\u00e1rio de Santa Maria (CHULN), Lisboa, Portugal"}]},{"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Servi\u00e7o de Reumatologia, Centro Hospitalar Universitario Lisboa Norte (CHULN), Lisboa, Portugal"}]},{"given":"Joaquim J","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Farmacologia Clinica e Terap\u00eautica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"CNS - Campus Neurol\u00f3gico S\u00e9nior, Torres Vedras, Portugal"}]},{"given":"Fausto J","family":"Pinto","sequence":"additional","affiliation":[{"name":"Centro Cardiovascular da Universidade de Lisboa (CCUL), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Cardiology Department, Hospital Universit\u00e1rio de Santa Maria (CHULN), Lisboa, Portugal"}]},{"given":"Daniel","family":"Caldeira","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Farmacologia Clinica e Terap\u00eautica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Centro Cardiovascular da Universidade de Lisboa (CCUL), Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal"},{"name":"Cardiology Department, Hospital Universit\u00e1rio de Santa Maria (CHULN), Lisboa, Portugal"}]}],"member":"239","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"2025090312153348000_7.2.e001678.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2025090312153348000_7.2.e001678.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09037.x"},{"key":"2025090312153348000_7.2.e001678.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02362.x"},{"key":"2025090312153348000_7.2.e001678.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22066"},{"key":"2025090312153348000_7.2.e001678.5","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90473-Z"},{"key":"2025090312153348000_7.2.e001678.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.053"},{"key":"2025090312153348000_7.2.e001678.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.4832"},{"key":"2025090312153348000_7.2.e001678.8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"2025090312153348000_7.2.e001678.9","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-307489"},{"key":"2025090312153348000_7.2.e001678.10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0040-1716752","article-title":"Satisfaction of patients with Nonvitamin K anticoagulants compared to vitamin K antagonists: a systematic review and meta-analysis","volume":"121","author":"Katerenchuk","year":"2021","journal-title":"Thromb Haemost"},{"key":"2025090312153348000_7.2.e001678.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"2025090312153348000_7.2.e001678.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"2025090312153348000_7.2.e001678.13","unstructured":"Higgins P , Savovic H , Page M . Revised Cochrane risk-of-bias tool for randomized trials (rob 2) short version (CRIBSHEET), RoB 2.o Dev GR. 366, 2019."},{"key":"2025090312153348000_7.2.e001678.14","unstructured":"Sterne JA , Hern\u00e1n MA , Reeves BC . The risk of bias in Non-randomized studies \u2013 of interventions (ROBINS-I) assessment tool ROBINS-I tool (stage I): at protocol stage, 2016: 1\u201322."},{"key":"2025090312153348000_7.2.e001678.15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pcd.2019.11.004","article-title":"Aspirin in the primary prevention of cardiovascular disease on diabetic patients: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2020","journal-title":"Prim Care Diabetes"},{"key":"2025090312153348000_7.2.e001678.16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2025090312153348000_7.2.e001678.17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.repc.2014.01.013","article-title":"The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis","volume":"33","author":"Caldeira","year":"2014","journal-title":"Rev Port Cardiol"},{"key":"2025090312153348000_7.2.e001678.18","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2025090312153348000_7.2.e001678.19","unstructured":"Jonathan E , Sterne AC , Egger M , et al . Chapter 10 CO, 2017. Available: www.training.cochrane.org\/handbook"},{"key":"2025090312153348000_7.2.e001678.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"2025090312153348000_7.2.e001678.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"2025090312153348000_7.2.e001678.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848333"},{"key":"2025090312153348000_7.2.e001678.23","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"2025090312153348000_7.2.e001678.24","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0291"},{"key":"2025090312153348000_7.2.e001678.25","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X16668588"},{"key":"2025090312153348000_7.2.e001678.26","first-page":"80","article-title":"[Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Results of the RE-COVER study]","volume":"50","author":"Liakishev","year":"2010","journal-title":"Kardiologiia"},{"key":"2025090312153348000_7.2.e001678.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004450"},{"key":"2025090312153348000_7.2.e001678.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113697"},{"key":"2025090312153348000_7.2.e001678.29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185132"},{"key":"2025090312153348000_7.2.e001678.30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0961203319889156","article-title":"Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study","volume":"29","author":"Malec","year":"2020","journal-title":"Lupus"},{"key":"2025090312153348000_7.2.e001678.31","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/0961203319881200","article-title":"Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study","volume":"28","author":"Sato","year":"2019","journal-title":"Lupus"},{"key":"2025090312153348000_7.2.e001678.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.07.030"},{"key":"2025090312153348000_7.2.e001678.33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.thromres.2020.11.014","article-title":"Heavy menstrual bleeding in women on oral anticoagulants","volume":"197","author":"Samuelson Bannow","year":"2021","journal-title":"Thromb Res"},{"key":"2025090312153348000_7.2.e001678.34","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.clinthera.2017.05.358","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses","volume":"39","author":"Almutairi","year":"2017","journal-title":"Clin Ther"},{"key":"2025090312153348000_7.2.e001678.35","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. results from an international patient-level data meta-analysis","volume":"17","author":"Dufrost","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025090312153348000_7.2.e001678.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-299099"},{"key":"2025090312153348000_7.2.e001678.37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/09537104.2017.1280150","article-title":"The role of platelets in antiphospholipid syndrome","volume":"28","author":"Baroni","year":"2017","journal-title":"Platelets"},{"key":"2025090312153348000_7.2.e001678.38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03928.x"},{"key":"2025090312153348000_7.2.e001678.39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01166.x"},{"key":"2025090312153348000_7.2.e001678.40","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.464"},{"key":"2025090312153348000_7.2.e001678.41","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.clinthera.2019.06.015","article-title":"Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: a systematic literature review and meta-analysis","volume":"41","author":"Sanchez-Redondo","year":"2019","journal-title":"Clin Ther"},{"key":"2025090312153348000_7.2.e001678.42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.14398","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis","volume":"17","author":"Elsebaie","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2025090312153348000_7.2.e001678.43","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102711","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"20","author":"Dufrost","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2025090312153348000_7.2.e001678.44","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/0961203320914363","article-title":"Catastrophic antiphospholipid syndrome following the introduction of rivaroxaban","volume":"29","author":"Stammler","year":"2020","journal-title":"Lupus"},{"key":"2025090312153348000_7.2.e001678.45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2017.03.006","article-title":"Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban","volume":"153","author":"Crowley","year":"2017","journal-title":"Thromb Res"},{"key":"2025090312153348000_7.2.e001678.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025759"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:15:42Z","timestamp":1756926942000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,7,12]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/rmdopen-2021-001678"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001678","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}